^
BIOMARKER:

RUNX1 mutation

i
Other names: RUNX1, RUNX Family Transcription Factor 1, Runt-Related Transcription Factor 1, Polyomavirus Enhancer-Binding Protein 2 Alpha B Subunit, SL3/AKV Core-Binding Factor Alpha B Subunit, SL3-3 Enhancer Factor 1 Alpha B Subunit, Runt Related Transcription Factor 1, Acute Myeloid Leukemia 1 Protein, Oncogene AML-1, PEBP2-Alpha B, PEA2-Alpha B, AMLCR1, CBFA2, AML1, Core-Binding Factor Subunit Alpha-2, AML1-EVI-1 Fusion Protein, Acute Myeloid Leukemia 1, Aml1 Oncogene, CBF-Alpha-2, AML1-EVI-1, PEBP2alpha
Entrez ID:
Related biomarkers:
RUNX1 mutation
AML
venetoclax
Sensitive: C2 – Inclusion Criteria
Blood Adv - 2 weeks
RUNX1 mutation
MDS
ruxolitinib
Sensitive: A2 - Guideline
RUNX1 mutation
CMML
venetoclax
Sensitive: C2 – Inclusion Criteria
RUNX1 mutation
MDS
venetoclax
Sensitive: C2 – Inclusion Criteria
RUNX1 mutation
MDS
pembrolizumab
Sensitive: C3 – Early Trials
RUNX1 mutation
AML
venetoclax + RO5503781
Sensitive: C3 – Early Trials
RUNX1 mutation
AML
LY3009120
Resistant: C3 – Early Trials
RUNX1 mutation
AML
cytarabine/daunorubicin liposomal formulation
Resistant: C3 – Early Trials
RUNX1 mutation
AML
cytarabine
Resistant: C3 – Early Trials
RUNX1 mutation
MDS
azacitidine
Resistant: C3 – Early Trials
RUNX1 mutation
AML
cytarabine + clofarabine
Sensitive: C3 – Early Trials
RUNX1 mutation
AML
cytarabine + cladribine
Sensitive: C3 – Early Trials
RUNX1 mutation
AML
decitabine + clofarabine
Sensitive: C3 – Early Trials
RUNX1 mutation
AML
decitabine + cladribine
Sensitive: C3 – Early Trials
RUNX1 mutation
AML
CDIAG
Sensitive: C3 – Early Trials
RUNX1 mutation
AML
tagraxofusp
Sensitive: D – Preclinical